Abacus Life, Inc. Prices Public Offering of $25 Million Additional 9.875% Notes Due 2028
- None.
- None.
Abacus Life's decision to price an underwritten public offering of $25 million in additional notes is a strategic move aimed at optimizing its capital structure. The high interest rate of 9.875% indicates the company is willing to pay a premium to attract investors, which could suggest a higher risk profile or a need for immediate capital. The fungibility with existing notes provides liquidity and uniformity in the market, which could enhance the notes' attractiveness to fixed-income investors. However, the rate is notably higher than current average corporate bond yields, which hover around 3-4% for investment-grade companies, indicating Abacus may be perceived as a higher risk investment.
The use of proceeds to refinance other outstanding indebtedness is a common strategy that could potentially lower overall interest expenses and extend debt maturities, improving financial flexibility. Investors should closely monitor the company's leverage ratios and interest coverage to assess the sustainability of its debt levels post-offering. The overallotment option is standard practice, offering underwriters flexibility to manage demand and stabilize the notes' post-issuance market price.
Listing the New Notes on the Nasdaq Global Market under the same symbol as the Existing Notes should provide seamless integration into the market, facilitating trading and potentially enhancing liquidity. This is important for investors who may seek to trade the notes in the secondary market. The choice of Piper Sandler & Co., A.G.P./Alliance Global Partners and Ladenburg Thalmann & Co. Inc. as joint book-running managers reflects a reliance on experienced underwriters, which could instill confidence in potential investors regarding the handling of the offering.
However, it's crucial for investors to consider the current economic environment, where rising interest rates could impact the attractiveness of fixed-income securities. If market rates increase further, the New Notes might lose some appeal, unless they offer a yield that compensates for the rate risk. Additionally, investors should be aware of the potential dilution of the existing note holders' interests, as the additional issuance increases the total debt outstanding, which could affect the recovery rate in the event of default.
The engagement of Locke Lord LLP and Alston & Bird LLP as legal counsel for the company and the underwriters, respectively, underscores the importance of due diligence in the offering process. The adherence to SEC regulations, as evidenced by the effectiveness of the registration statement, is crucial for the legitimacy of the offering. It's also important to note that the press release explicitly states that the New Notes will not be sold where it would be unlawful prior to registration or qualification under the securities laws of those jurisdictions. This highlights the legal complexities surrounding securities offerings and the need for potential investors to be aware of the legal framework governing the issuance and sale of such financial instruments.
ORLANDO, Fla., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL; ABLLL) today announced that it has priced an underwritten public offering of
The Company expects to use the net proceeds from this offering to refinance other outstanding indebtedness and for general corporate purposes.
The Existing Notes are listed and trade on the Nasdaq Global Market® under the symbol “ABLLL” and the Company intends to apply to list the New Notes on the Nasdaq Global Market® under the same symbol.
Investors are advised to consider carefully the investment objective, risks and charges and expenses of the Company before investing.
Locke Lord LLP acts as legal counsel to the Company, and Alston & Bird LLP acts as legal counsel to the underwriters.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of, the New Notes referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. A registration statement relating to these securities was filed and has been declared effective by the Securities and Exchange Commission (the “SEC”).
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained for free by visiting the SEC's website at www.sec.gov or from the underwriters by contacting: Piper Sandler & Co. by mail at 1251 Avenue of the Americas, 6th Floor, New York, NY 10020, or by email at fsg-dcm@psc.com. The preliminary prospectus contains a description of these matters and other important information about the Company and should be read carefully before investing.
About Abacus Life, Inc.
Abacus is a leading vertically integrated alternative asset manager and market maker, specializing in longevity and actuarial technology. The company is democratizing the life insurance space through groundbreaking new channels: ABL Tech, ABL Wealth, and ABL Longevity Growth and Income Funds. Since 2004, Abacus has purchased life insurance policies from consumers seeking liquidity and has actively managed those policies over time (via trading, holding, and/or servicing). With over
Over the past 20 years, the company has built an institutionalized origination and portfolio management process that is supported by a 100+ person team, long-term relationships with 78 institutional partners and 30,000 financial advisors, and the ability to operate in 49 states. The Company complies with HIPAA and privacy laws to maintain and protect confidentiality of financial, health, and medical information. Abacus is also proud to be a BBB Accredited Business with an A+ rating.
Forward-Looking Statements
This communication contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction, including statements regarding the anticipated benefits of the transaction, the future financial condition and performance of the Company and expected financial impacts of the transaction (including future revenue and pro forma enterprise value) and the platform and markets and expected future growth and market opportunities of Abacus. These forward-looking statements generally are identified by the words “believe,” “predict,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “scales,” “representative of,” “valuation,” “potential,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions or the negatives of these terms or variations of them. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are inherently subject to risks and uncertainties. These forward‐looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are beyond Abacus’s control, are difficult or impossible to predict and may differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that demand for Abacus’s life settlement and related offerings does not grow as expected, (ii) the ability of Abacus to retain existing customers and attract new customers, (iii) the potential inability of Abacus to manage growth effectively, (iv) the potential inability of Abacus to grow its market share of the life settlement industry or to achieve efficiencies regarding its operating model or other costs, (v) negative trends in the life settlement industry impacting the value of life settlements, including increases to the premium costs of life insurance policies, increased longevity of insureds, and errors in the methodology and assumptions of life expectancy reports, (vi) legal challenges by insurers relating to the validity of the origination or assignment of certain life settlements, (vii) the enforceability of Abacus’s intellectual property rights, including its trademarks and trade secrets, and the potential infringement on the intellectual property rights of others, (viii) Abacus’s dependence on senior management and other key employees, and (ix) the risk of downturns and a changing regulatory landscape in the industry in which Abacus operates. The foregoing list of factors is not exhaustive.
Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should carefully consider the foregoing factors and the other risks and uncertainties which will be more fully described in the documents filed by Abacus from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers of this communication are cautioned not to put undue reliance on forward-looking statements, and Abacus assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Abacus gives no assurance that it will achieve expectations.
Contacts:
Abacus Life Investor Relations
investors@abacuslife.com
Abacus Life Public Relations
press@abacuslife.com
FAQ
What is the purpose of Abacus Life, Inc.'s public offering?
What is the total amount of the notes outstanding after the new offering?
Who are the joint book-running managers for the offering?
Where will the New Notes be listed for trading?
How can investors obtain a copy of the preliminary prospectus?
